R&D Pipeline
| Product | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Pre-registration | Approved / Market |
|---|---|---|---|---|---|---|---|---|
| Elepsia® XR (Levetiracetam ER) | Epilepsy |
|
||||||
| Xelpros® (Latanoprost BAK Free) | Glaucoma |
|
||||||
| Phenobarbital Injection | Neonatal Seizure |
|
||||||
| SDN – 037 | Ocular Pain & Inflammation |
|
||||||
| PDP - 716 | Glaucoma |
|
||||||
| SCO – 088 | CML |
|
||||||
| SCC - 138 | Parkinson’s Disease |
|
||||||
| SCD – 044 | Autoimmune Disorders |
|
||||||
| SCO - 120 | Breast Cancer |
|
||||||
| Product | Elepsia® XR (Levetiracetam ER) |
| Indication | Epilepsy |
| Phase in US | Pre-registration |
| Product | Xelpros® (Latanoprost BAK Free) |
| Indication | Glaucoma |
| Phase in US | Approved / Market |
| Product | Phenobarbital Injection |
| Indication | Neonatal Seizure |
| Phase in US | Phase 3 |
| Product | SDN – 037 |
| Indication | Ocular Pain & Inflammation |
| Phase in US | Phase 3 |
| Product | PDP - 716 |
| Indication | Glaucoma |
| Phase in US | Phase 3 |
| Product | SCO – 088 |
| Indication | CML |
| Phase in US | Phase 2 |
| Product | SCC - 138 |
| Indication | Parkinson’s Disease |
| Phase in US | Phase 2 |
| Product | SCD – 044 |
| Indication | Autoimmune Disorders |
| Phase in US | Phase 2 |
| Product | SCO - 120 |
| Indication | Breast Cancer |
| Phase in US | Phase 1 |
